Earnings: Teva Pharma shrinks Q4 losses, but revenue falls

Teva Pharma (TEVA) posted its fourth-quarter 2018 before the opening bell on Feb. 13.┬áThe generic drugmaker saw revenue slip 16% to $4.56 billion in the quarter, while net attributable loss shrunk to $2.94 billion or $2.85 per diluted share vs. $11.6 billion or $11.41-a-share in losses a year ago. Non-GAAP profit slipped to $543 million … Continue reading Earnings: Teva Pharma shrinks Q4 losses, but revenue falls